Non-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy
- Dexcom G6 is the first Continuous Glucose Monitoring (CGM) System to be listed by the NIHB Drug Benefit program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210913005728/en/
“Indigenous, First Nations and Inuit communities are disproportionately impacted by diabetes, yet I’ve seen how greater access to CGM for this population can mean better glucose control, which leads to improved health outcomes and reduced risk of developing diabetes-related complications,” said Dr.
Dexcom CGM use is proven to improve glycemic control1,2 and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring.3 As part of the
“Expanded access to CGM for clients enrolled in
The Dexcom G6 CGM System includes a small, wearable sensor that measures glucose just below the skin; a transmitter to continuously and wirelessly send glucose levels to a display device; and a compatible smart device* or receiver that displays real-time glucose data to users without the need for fingersticks† or scanning.
With real-time alerts, including a predictive Urgent Low Soon alert, the Dexcom G6 can warn the user in advance of hypoglycemia — allowing time to take appropriate action before it happens — day or night. When using the Dexcom Follow App‡, parents can also access their child's glucose levels remotely and be alerted if they are going out of target glucose range.
For more information about the coverage criteria for Non-Insured Health Benefits clients, please visit www.dexcom.com/en-CA/public-coverage.
To search the online NIHB Drug Benefit List for Dexcom G6 coverage details, go to https://nihb.express-scripts.ca/NIHBProvider/benefits/pharmacy?page=drugbenefit-grid&benefit=pharmacy
† If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
* For a list of compatible devices, please visit dexcom.com/compatibility
‡ Following requires the Dexcom Follow App and an Internet connection. Followers should always confirm readings on the Dexcom G6 App or Receiver before making treatment decisions.
1Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017;317(4):371-8.
2Welsh JB, Gao P, Derdzinski M, et al. Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems. Diabetes Technol Ther 2019;21(3):128-32.
3 Roze S, Isitt J,